Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P250003/S010

Embrace(TM) Hydrogel Embolic System

Instylla, Inc. · Decision date Oct 21, 2026

MEDTECHLEDGER EXPLANATIONP250003/S010

What did the FDA approve?

The FDA recorded approval on 2026-10-21 of P250003/S010, a Special (Immediate Track) supplement to the Embrace Hydrogel Embolic System PMA held by Instylla, Inc. The supplement type is listed under the process-change reason covering manufacturer, sterilizer, packager or supplier, and the device category is Embolization Agent, Vascular.

The reported purpose is a change to product positioning within the pouch before moist heat sterilization of the precursor kit. This is a manufacturing notice about the precursor kit, not a new approval of the whole system and not an original PMA. The record does not specify the prior positioning, the new positioning, the pouch or kit components affected, or any sterilization validation outcomes; safety or clinical effectiveness is not established by this entry.

The identifier P250003/S010 links the supplement to parent PMA P250003.

FDA approval order statement

Approval for a change to the product positioning within the pouch prior to moist heat sterilization of the precursor kit of the Embrace Hydrogel Embolic System (HES).
Regulatory pathway
PMA supplement
Supplement type
Special (Immediate Track)
Clinical specialty
Cardiovascular
Decision date
Oct 21, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P250003/S010
Regulatory pathway
PMA supplement
Product code
QVG
Decision code
APPR
Decision date
Oct 21, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Embolization Agent, Vascular.

Product code
QVG
FDA device class
3

For the original device and its historical approval scope, see PMA P250003. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P250003 · Original PMA

    Embrace(TM) Hydrogel Embolic System

  2. P250003/S009 · Related supplement

    Embrace Hydrogel Embolic System

  3. P250003/S010 received

    Application receipt date recorded by FDA.

  4. P250003/S010 · FDA decision

    Special (Immediate Track)

  5. P250003/S008 · Related supplement

    Embrace(TM) Hydrogel Embolic System

  6. P250003/S011 · Related supplement

    Embrace Hydrogel Embolic System

Timeline entries are records held by MedtechLedger for P250003. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P250003

Product / regulatory recordCompanyPathwayDecision dateSource
Instylla, Inc.PMA approvalAug 5, 2025FDA
Instylla, Inc.PMA supplementSep 3, 2026FDA
Instylla, Inc.PMA supplementOct 23, 2026FDA
Instylla, Inc.PMA supplementOct 23, 2026FDA

Explore the linked device profile

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Instylla, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
201 Burlington Rd., North Bldg., Bedford, MA, 01730

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records